Newsletter Signup | Join Community
Gilotrif as a single agent or in combination improves survival in EGFR + NSCLC.
Treatment of multiple myeloma and cancers that spread to bone all benefit from XGEVA treatment.
Understand the role of PET/CT scanning in the management of Non-Small Cell Lung Cancer.
FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation.
IMPower133 clinical trial leads to Tecentriq being first new approved initial treatment for SCLC in years.
PCI may improve survival in small cell lung cancer; new study suggests some benefit in early stage NSCLC.
The precision cancer medicine Tarceva targeting EGFR improves survival in stage I-III NSCLC & appears better than chemo!
Lung Cancer; Risk factors, diagnostic evaluation, staging and treatment planning.
Lung-MAP Precision Medicine Clinical Trial expanded to include all types of NSCLC including squamous and adenocarcinoma.
Stay Current With Lung Cancer Treatment Advances & Connect with Others
Tarceva™ Improves Survival in Non-Small Cell Lung Cancer
I have small cell lung cancer; radiation to prevent spread to the brain has been recommended but…
HER 2 + Lung Cancer Treatment? https://coloradocancerblogs…
Dana Farber and MDACC discover why anti-PD 1 immunotherapy doesnt work in some patients and work to…
High incidence of ROS 1 false negative tests reported by U Colorado researchers. http://www…